A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Akeso and Summit Therapeutics' bispecific antibody ivonescimab (PD-1/VEGF) reduced mortality risk by 34% in a Phase 3 China trial, extending median overall survival to 27.9 months vs. 23.7 months for standard PD-1 plus chemotherapy in squamous NSCLC. The data reignite the debate over whether PD-1/VEGF combos can succeed Keytruda ($30B+ in annual sales) as the standard-of-care backbone, though generalizability outside China remains unconfirmed until Harmoni-3 global results land in H2 2026.